What's in Hopital Foch's pipeline?

Hopital Foch has 4 drugs in our index: 3 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Hopital Foch's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hopital-foch.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Hopital Foch — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hopital Foch pipeline: 3 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Target	Area
Rituximab Injection	Rituximab Injection	marketed
Gelatin 500 mL	Gelatin 500 mL	marketed
Propofol Fresenius plus lidocaine	Propofol Fresenius plus lidocaine	marketed
Ursolvan	Ursolvan	phase 3	Aldo-keto reductase family 1 member C2, CDGSH iron-sulfur domain-containing protein 1, Ectonucleotide pyrophosphatase/phosphodiesterase family member 2	Other

Therapeutic area mix

Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Hopital Foch:

Cite this brief

Drug Landscape (2026). Hopital Foch — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hopital-foch. Accessed 2026-05-17.